Slice of Healthcare’s Post

March is #MyelomaActionMonth. It is estimated that this year alone over 35,000 new cases of Myeloma will be diagnosed. Let's take actions that positively impact the myeloma community. Learn more from and take action with the International Myeloma Foundation here: https://lnkd.in/enieFAbQ

🏁 Thrilled to announce the completion of the comprehensive project for Omdena's Silicon Valley Chapter, focused on the development of cutting-edge computer vision and natural language processing (NLP) solutions. 👨🏫 Mentorship and Knowledge Sharing: Throughout the project journey, I provided mentorship and guidance on advanced computer vision techniques. The collaborative atmosphere allowed us to share insights and skills, enhancing everyone's expertise in the field. 🤖 Computer Vision and NLP Fusion: I not only tackled complex computer vision projects but also ventured into the realm of natural language processing. This fusion of technologies broadened our understanding of AI's potential and enabled us to address multifaceted challenges. 🚀 Timely Project Deliveries: One of the hallmarks of my journey was our commitment to meeting deadlines. We took pride in delivering high-quality work within the stipulated time frame, ensuring that project milestones were achieved as planned. 🛠️ End-to-End Project Pipeline: The project's success hinged on our ability to craft an end-to-end pipeline, seamlessly integrating computer vision and NLP components. From data collection to model deployment, we navigated the entire process efficiently. 🙌 I express our gratitude to Kseniya Trusova, Nishrin K. and the entire Omdena Silicon Valley Chapter community for their incredible support, collaboration, and shared commitment to driving AI for good. This endeavor has been an inspiring learning journey, and we look forward to further advancing the frontiers of AI technology. Please do have a look at the final project at Github and reach out if you have any queries or need support to replicate the project. #AIForGood #Omdena #Healthcare #ComputerVision #NLP #EndToEndPipeline #machinelearning #AI #ArtificialIntelligence

Tomorrow, the winners of the £40 million LifeArc Rare Disease Challenge will be revealed! 🎉    This is a game-changer for the millions battling rare diseases with limited treatment options.     Following her keynote address at the launch of the LifeArc Rare Disease Challenge last year, Weatherden's Drug Development Clinician and PCD research Chair, Dr Harriet Holme MD PhD, returns to the LifeArc Translational Science Summit alongside one of our Strategy Directors, Steven Robery.    Why is this such a big deal?  - Over 8,000 rare diseases exist,   - Over 3.5 million people in the UK, and over 300 million people worldwide are living with rare diseases,  - 95% of rare diseases lack approved treatments.    LifeArc's Rare Disease Challenge is a landmark investment in the fight for rare disease solutions. This aligns perfectly with Weatherden's mission. We use our translational medicine expertise to double the success rate of clinical trials, speeding up the path to effective treatments for patients. 🚀    Join us in London on April 23rd! Let's connect there - or learn more about our work reshaping clinical development at https://weatherden.co.uk/    #LifeArc #TranslationalScience #TranslationalMedicine #ClinicalDevelopment #Pharma  

⭐Multiple Myeloma Hub spotlight: Updated data from the phase II KarMMa-2 trial ⭐ At #EHA2024, Xavier Leleu from Poitiers University Hospital discussed results from Cohort 2B of the phase II KarMMa-2 trial (NCT03601078) investigating the safety and efficacy of ide-cel in patients with clinical high-risk early-relapse MM without frontline ASCT (N = 31). The primary endpoint of CRR was achieved in 71% pts, highlighting the potential for ide-cel use in earlier lines of treatment. #mmsm #myeloma 

🚀 Attention Investors and Healthcare Leaders! 🚀 R3i are thrilled to celebrate StratifiCare™ Pte. Ltd.'s CEO, Anthony Chua, who just landed in Dallas, Texas, to accelerate the progress of two revolutionary personalized medicine diagnostics: 🌟 Stratifiden - The world's first severe dengue prognostic that reduces unnecessary hospitalization by 67%, easing the emotional and financial burden on families. 🌟 Stratifirey - The world's first liver cancer diagnostic that predicts patient response to Y90 RE treatment, allowing clinicians to make informed decisions and reduce the agonizing 3 to 6-month wait for results. StratifiCare's journey is a testament to perseverance and innovation. To develop these groundbreaking products, it secured $35M in non-dilutive capital and less than $1M in venture capital. Anthony Chua's unwavering determination teaches us the power of persistence and the impact of every step forward. A special thank you to David Jacobson for welcoming StratifiCare™ Pte. Ltd. into our Texas triangle and the SMU Cox School of Business community. 💡 Investors and hospital administrators, this is your chance to be part of a transformative journey in personalized medicine. Reach out and learn how you can support and benefit from these pioneering advancements. Together let's accelerate impact 💡 NUS Overseas Colleges National University of Singapore Singapore Economic Development Board (EDB) #HealthcareInnovation #PersonalizedMedicine #DengueDiagnostic #LiverCancerDiagnostic #StratifiCare #InvestmentOpportunities #HealthcareLeaders #MedicalBreakthroughs #Valuebasedcare Enterprise Singapore

Planning and conducting clinical trials for #rarediseases can be challenging in so many ways. Bionical Emas, in collaboration with TrialHub, tackled these challenges together and revolutionized the planning of a Phase 4 Tuberous Sclerosis Complex trial. This case study showcases the power of #data in overcoming rare disease clinical trial challenges, significantly reducing timeline constraints. Here are insights and strategies that made this success possible. 👇

📝New paper: “Optimizing diagnostic networks to increase patient access to #TB diagnostic services: Development of the diagnostic network optimization (DNO) approach and learnings from its application in #Kenya, #India and the #Philippines" Co-Authored by Heidi Albert et al. This paper demonstrates the value of #DNO as an innovative and open-access approach particularly suited for use in low-resource settings, that can be applied to optimize networks for any disease. Read more here: https://lnkd.in/dHzF66U2 #DiagnosisForAll Heidi Albert, Dr Sarabjit Chadha, Kekeletso Kao, Zachary Katz

🌟 Highlighting one of our many best cases🌟 🌟 Emovis is proud to have conducted a groundbreaking Phase IIb study for Oryzon Genomics S.A., focusing on the promising compound Vafidemstat for Borderline Personality Disorder (BPD).🌟 🚀 We initiated patient enrollment mid-2022, and the response has been phenomenal: - 💬 Over 1,000 inquiries in just six months! - 🥇 Making this study our top priority for 2022. 🤝 This success reflects: - 🌐 Our diverse and sophisticated recruitment strategies. - 💪 The dedication of our study center. 🔍 What sets Vafidemstat apart? - ✅ Vafidemstat, an oral capsule, targets the enzyme LSD1 to reduce internal agitation and aggression, improving the BPD condition. - 📊 Previous clinical trials have shown its potential as a safe and well-tolerated treatment option. 📈 It also underscores the urgent need for innovative BPD therapies. Current treatments often fall short or come with significant side effects. 👏 emovis is confident in achieving recruitment goals and we extend our gratitude to our study sponsors for their trust and support. Let's make a difference together! #clinicaltrials and follow us for more on FutureMeds!

This review provides an interesting overview of the clinical landscape of CDK4/6 inhibitors in the treatment of HR+, HER2-negative #BreastCancer, highlighting potential biomarkers associated with intrinsic and acquired resistance to CDK4/6is.

This review provides an interesting overview of the clinical landscape of CDK4/6 inhibitors in the treatment of HR+, HER2-negative #BreastCancer, highlighting potential biomarkers associated with intrinsic and acquired resistance to CDK4/6is.